| |
AD (n= 54)
|
MCI (n= 75)
|
Controls (n= 25)
|
|---|
|
Age, years
|
75 (6.2)
|
68 (9.3)
|
74 (6.7)
|
|
Gender, male/female
|
17/37
|
29/46
|
6/19
|
|
MMSE, score
|
19 (4.9)a
|
27 (1.6)
|
29 (1.4)
|
|
Plasma T-tau, pg/mL
|
8.80 (10.1)b,c
|
4.68 (4.25)
|
4.43 (2.83)
|
|
CSF T-tau, pg/mL
|
828 (375)a
|
550 (421)
|
507 (254)
|
|
CSF P-tau, pg/mL
|
123 (49.2)a
|
78.1 (28.8)
|
73.4 (20.5)
|
|
CSF Aβ42, pg/mL
|
380 (87.6)a
|
478 (204)
|
584 (215)
|
- Quantitative data are presented as mean (standard deviation). Statistical differences were determined by using nonparametric tests. Cerebrospinal fluid (CSF) biomarker concentrations are INNOTEST ELISA-normalized Luminex AlzBio3 (Innogenetics, Gent, Belgium) values. aCompared with patients with mild cognitive impairment (MCI) or controls, P <0.001. bCompared with patients with MCI, P = 0.001. cCompared with controls, P = 0.02. AD, Alzheimer's disease; MMSE, mini-mental state examination.
